{"id":743008,"date":"2023-03-28T07:08:22","date_gmt":"2023-03-28T11:08:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/"},"modified":"2023-03-28T07:08:22","modified_gmt":"2023-03-28T11:08:22","slug":"silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/","title":{"rendered":"Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development<\/b><\/p>\n<p class=\"bwalignc\"><i>Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&amp;D, following his retirement by year-end<\/i><\/p>\n<p>LONDON&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nSilence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), an experienced and innovative biotechnology company committed to transforming people\u2019s lives by silencing diseases through precision engineered medicines, today announced the appointment of Steven Romano, MD, as incoming<b \/>Chief Medical Officer and Head of Research and Development. Dr. Romano will join Silence on April 1, 2023, and work alongside Giles Campion, MD, current CMO and Head of R&amp;D at Silence, to ensure an efficient and smooth transition for Dr. Campion\u2019s retirement by year-end.\n<\/p>\n<p>\nDr. Romano has served as non-executive director of the Silence Board since July 2019 following the Company\u2019s siRNA collaboration with Mallinckrodt plc for complement-mediated diseases. Since then, Dr. Romano has played a key role overseeing the company\u2019s complement portfolio. In a press release issued this morning, Silence announced that it was buying back two of its siRNA assets from Mallinckrodt.\n<\/p>\n<p>\n\u201cGiles has been instrumental in leading our R&amp;D efforts to get Silence to where it is today \u2013 a clinical stage company advancing multiple programs \u2013 and we are grateful for his continued dedication to the company,\u201d said Craig Tooman, President and CEO of Silence. \u201cWe are very pleased to welcome Steven Romano to our executive team in this crucial role as we enter the next chapter of innovation and growth at Silence. His extensive experience overseeing research and development, regulatory and medical affairs make him the ideal leader to advance our clinical activities and pursue new opportunities to maximize our mRNAi GOLD<sup>\u2122<\/sup> platform technology.\u201d\n<\/p>\n<p>\n\u201cBeing a member of the Silence Board since July 2019, I\u2019ve developed a deep understanding and appreciation for the company\u2019s siRNA platform technology to address a broad range of genetic diseases,\u201d said Steven Romano, MD. \u201cI\u2019m honored to assume the leadership of Silence\u2019s R&amp;D organization and look forward to building on this strong momentum to help bring transformative medicines to people around the world.\u201d\n<\/p>\n<p>\nDr. Romano is also a board-certified psychiatrist with more than 25 years of experience in the pharmaceutical industry, including 16 years at Pfizer. Most recently, he served as executive vice president and chief scientific officer at Mallinckrodt and was responsible for research and development, medical affairs, health economics and outcomes research, safety, pharmacovigilance and regulatory affairs functions. At Pfizer, Dr. Romano served in a series of senior roles, including Senior Vice President, Head, Global Medicines Development, Global Innovative Pharmaceuticals Business. Before Pfizer, he spent four years at Eli Lilly performing clinical research. Dr. Romano received his bachelor\u2019s degree in biology from Washington University in St. Louis and his medical degree from the University of Missouri-Columbia. He completed his residency and fellowship at New York Hospital-Cornell Medical Center, where he then served on the medical school faculty for six years.\n<\/p>\n<p><b>About Silence Therapeutics<br \/>\n<br \/><\/b>Silence Therapeutics is developing a new generation of medicines by harnessing the body\u2019s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence\u2019s proprietary mRNAi GOLD<sup>\u2122<\/sup> platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence\u2019s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address rare hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.silence-therapeutics.com%2F&amp;esheet=53368977&amp;newsitemid=20230328005336&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.silence-therapeutics.com%2F&amp;index=1&amp;md5=70a9e219b75667c33b057d5c15fadab7\">https:\/\/www.silence-therapeutics.com\/<\/a>.\n<\/p>\n<p><b>Forward-Looking Statements<br \/>\n<br \/><\/b>Certain statements made in this announcement are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other securities laws, including with respect to the Company\u2019s clinical and commercial prospects, regulatory approvals of the Company\u2019s product candidates, potential partnerships or collaborations or payments under new and existing collaborations, the initiation or completion of the Company\u2019s clinical trials and the anticipated timing or outcomes of data reports from the Company\u2019s clinical trials. These forward-looking statements are not historical facts but rather are based on the Company&#8217;s current assumptions, beliefs, expectations, estimates and projections about its industry. Words such as &#8216;anticipates,&#8217; &#8216;expects,&#8217; &#8216;intends,&#8217; &#8216;plans,&#8217; &#8216;believes,&#8217; &#8216;seeks,&#8217; &#8216;estimates,&#8217; and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company&#8217;s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including those risks identified in the Company\u2019s most recent Admission Document and its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d) on March 15, 2023. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230328005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230328005336\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230328005336\/en\/<\/a><\/span><\/p>\n<p><b>Enquiries:<\/b><\/p>\n<p><b>Silence Therapeutics plc<br \/>\n<\/b><br \/>Gem Hopkins, VP, Head of IR and Corporate Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@silence-therapeutics.com\">ir@silence-therapeutics.com<\/a><\/p>\n<p>\nTel: +1 (646) 637-3208\n<\/p>\n<p><b>KEYWORDS:<\/b> North America United States Ireland United Kingdom Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Cardiology Biotechnology Research Pharmaceutical Health Genetics Other Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230328005336\/en\/1748666\/3\/Silence-Logo-FINAL-rgb.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&amp;D, following his retirement by year-end LONDON&#8211;(BUSINESS WIRE)&#8211; Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), an experienced and innovative biotechnology company committed to transforming people\u2019s lives by silencing diseases through precision engineered medicines, today announced the appointment of Steven Romano, MD, as incomingChief Medical Officer and Head of Research and Development. Dr. Romano will join Silence on April 1, 2023, and work alongside Giles Campion, MD, current CMO and Head of R&amp;D at Silence, to ensure an efficient and smooth transition for Dr. Campion\u2019s retirement by year-end. Dr. Romano has &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-743008","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&amp;D, following his retirement by year-end LONDON&#8211;(BUSINESS WIRE)&#8211; Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), an experienced and innovative biotechnology company committed to transforming people\u2019s lives by silencing diseases through precision engineered medicines, today announced the appointment of Steven Romano, MD, as incomingChief Medical Officer and Head of Research and Development. Dr. Romano will join Silence on April 1, 2023, and work alongside Giles Campion, MD, current CMO and Head of R&amp;D at Silence, to ensure an efficient and smooth transition for Dr. Campion\u2019s retirement by year-end. Dr. Romano has &hellip; Continue reading &quot;Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-28T11:08:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230328005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development\",\"datePublished\":\"2023-03-28T11:08:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\\\/\"},\"wordCount\":1013,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230328005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\\\/\",\"name\":\"Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230328005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-03-28T11:08:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230328005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230328005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/","og_locale":"en_US","og_type":"article","og_title":"Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development - Market Newsdesk","og_description":"Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&amp;D, following his retirement by year-end LONDON&#8211;(BUSINESS WIRE)&#8211; Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), an experienced and innovative biotechnology company committed to transforming people\u2019s lives by silencing diseases through precision engineered medicines, today announced the appointment of Steven Romano, MD, as incomingChief Medical Officer and Head of Research and Development. Dr. Romano will join Silence on April 1, 2023, and work alongside Giles Campion, MD, current CMO and Head of R&amp;D at Silence, to ensure an efficient and smooth transition for Dr. Campion\u2019s retirement by year-end. Dr. Romano has &hellip; Continue reading \"Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-28T11:08:22+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230328005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development","datePublished":"2023-03-28T11:08:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/"},"wordCount":1013,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230328005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/","name":"Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230328005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-03-28T11:08:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230328005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230328005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-appoints-dr-steven-romano-as-incoming-chief-medical-officer-and-head-of-research-and-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/743008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=743008"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/743008\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=743008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=743008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=743008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}